Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion previously received EMA approval for Remsima™ which is the world’s first biosimilar mAb to receive approval from a regulatory agency in a developed country. For more information, please visit http://www.celltrion.com/EN
Location: South Korea, Incheon
Employees: 1001-5000
Phone: +82 32-850-5000
Founded date: 2002
Investors 2
| Date | Name | Website |
| - | Temasek Ho... | temasek.co... |
| - | SJL Partne... | sjlpartner... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 24.01.2024 | WuXi XDC and Celltrion Sign MOU for Integrated Services for ... | SHANGHAI and INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global... | en.prnasia... |
| 28.04.2022 | Celltrion USA Recalls Certain Point of Care DiaTrust COVID-1... | The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devic... | einpresswi... |
| 28.11.2018 | FDA approves Celltrion, Teva’s Rituxan biosimilar, but with ... | The biosimilar is approved as a single agent in patients with relapsed or refractory low-grade or fo... | medcitynew... |
| 11.10.2018 | Teva-partnered Celltrion biosimilar scores FDA adcomm... | After repeated run-ins with the FDA in the past few months regarding site inspections and bio... | endpts.com... |
| 01.02.2018 | UCB, investors back a neurosciences startup called Synd... | Dhavalkumar Patel, UCB → UCB and a syndicate of Belgian and international investors have j... | endpts.com... |
| - | FDA approves Celltrion, Teva’s Rituxan biosimilar, but with ... | The Food and Drug Administration has approved the first biosimilar version of a drug commonly used t... | medcitynew... |